1Koizumi M, Yomauchi T. Corrrelation between bone metabolic markers and bone scan in prostatic cancer[J]. J Unol,1997,157:539.
2Nakashima J, Sumitomo M, Miyajima A, et al . The value of serum carboxytreminal propeptide of type I procollagen in predicting bone metastases in prostate cancer[J]. J Urol,1997,157:1736.
3Yoshida K,Sumi S, Arai K, et al. Serum concentration of type Ⅰ collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma[J]. Cancer,1997,80:1760.
4Risreli J, Elomaa I, Niemi S, et al. Radioimmunoassay for the pyridinoline cross linked carboxyterminal telopeptide of type Ⅰ collagen: a new serum marker of bone resorption[J]. Clin Chem, 1993,39 : 635.
5Byers PH, Mckenney K H, Lichtenstein JR, et al. Preparation of type Ⅲ procollagen and collagen from rat skin[J]. Biochenmistry, 1974,13(25) : 5243.
6McCormick PJ, Chandrasekhar S, Mill AJT. Direct Visvalization of collagens and procollagens in polyacrylamide gels[J]. Anal Biochem, 1979,97 : 359.
7Parfitt AM, Simon LS, Villanueva AR, et al. Procollagen type Ⅰ carboxy-treminal extension peptide in serum as a marker of collagen biopynthesis in bone . Correlation with iliac bone formation rates and comparison with total alkaline phosphatase[J]. J Bone Miner Res, 1987,2 : 427.
8Melkko J, Niemi S,Ristell L, et al. Radioimmunoassay for the carboxyterminal propeptide of human type Ⅰ procollagen[J]. Clin Chem, 1990,36 : 1328.
